0196 Suppl.pdf (10.81 MB)
Download fileInfographic – Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas
figure
posted on 2022-07-12, 13:25 authored by Figshare Future Science GroupFigshare Future Science Group, Martin Wermke, Enriqueta Felip, Valentina Gambardella, Yasutoshi Kuboki, Daniel Morgensztern, Zohra Oum’ Hamed, Meiruo Liu, Matus Studeny, Taofeek K OwonikokoPhase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas
